Collaboration to focus on enabling clinicians to open clinical trials at the point of care.
Flatiron Health announced that it will be partnering with Penn Medicine to bring its Flatiron Assist to Penn’s Abramson Cancer Center (ACC). The project aims to further enable clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
“At Flatiron, we are committed to elevating clinical care and unlocking the power of patient data, so every person’s experience can inform and improve outcomes for future patients. Partnering with Penn Medicine’s Abramson Cancer Center, a market-leading cancer care provider and a pioneer of digital innovation in healthcare, enables us to use data for good and reimagine the infrastructure of cancer care,” said Julia Morton, SVP, GM, Flatiron HC. “We are looking forward to working together to accelerate the delivery of more standardized, efficient, and effective cancer care across the entire health system.”
Reference: Flatiron Health Launches New Strategic Collaboration to Advance Health Insights and Equity of Cancer Care. BusiessWire. October 23, 2023. Accessed October 23, 2023. https://www.businesswire.com/news/home/20231023565932/en/Flatiron-Health-Launches-New-Strategic-Collaboration-to-Advance-Health-Insights-and-Equity-of-Cancer-Care
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.